KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash & Equivalents (2016 - 2025)

Gilead Sciences (GILD) has disclosed Cash & Equivalents for 17 consecutive years, with $7.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 24.29% year-over-year to $7.6 billion, compared with a TTM value of $7.6 billion through Dec 2025, down 24.29%, and an annual FY2025 reading of $7.6 billion, down 24.29% over the prior year.
  • Cash & Equivalents was $7.6 billion for Q4 2025 at Gilead Sciences, up from $7.3 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $10.0 billion in Q4 2024 and bottomed at $2.8 billion in Q2 2024.
  • Average Cash & Equivalents over 5 years is $5.5 billion, with a median of $5.1 billion recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 66.15% in 2021, then soared 85.57% in 2025.
  • Year by year, Cash & Equivalents stood at $5.3 billion in 2021, then increased by 1.39% to $5.4 billion in 2022, then increased by 12.44% to $6.1 billion in 2023, then surged by 64.19% to $10.0 billion in 2024, then fell by 24.29% to $7.6 billion in 2025.
  • Business Quant data shows Cash & Equivalents for GILD at $7.6 billion in Q4 2025, $7.3 billion in Q3 2025, and $5.1 billion in Q2 2025.